Improvement After Celecoxib Treatment in Patients with Thalamic Hemorrhage - A Case Report
Journal
Acta neurologica Taiwanica
Journal Volume
31
Journal Issue
4
Pages
161
Date Issued
2022-12-30
Author(s)
Abstract
Perihematomal edema of intracerebral hemorrhage (ICH) is caused by a hematoma-induced inflammatory reaction, which usually contributes to delayed deterioration of neurological function and poor outcomes. Celecoxib is a commonly used nonsteroidal anti-inflammatory drug that selectively inhibits cyclooxygenase-2. High-dose celecoxib (400 mg twice daily) for 14 days has been shown to reduce perihematomal edema and hematoma enlargement in patients with ICH, but without improvement in long-term functional outcome, which may be confounded by the heterogeneity of hematoma location. Low-dose celecoxib may be an effective management for symptoms caused by perihematomal edema in patients with ICH, particularly those involving the thalamus.
Subjects
Brain edema; Celecoxib; Intracerebral hemorrhage.
SDGs
Type
journal article